By introducing its new product, ARBITWIN®, Cobel Darou has taken another major step in the field of hypertension management. ARBITWIN®, the third member of the highly successful ARBICOR® family, is a combination of two active ingredients—Telmisartan and Amlodipine—launched with the objective of providing sustained and effective control of high blood pressure.

Hypertension is the most significant risk factor for cardiovascular diseases, doubling the risk of coronary artery disease and stroke. According to statistics reported by the Ministry of Health and Medical Education (MOHME), over 18 million adults in Iran suffer from hypertension. High blood pressure is the 4th leading cause of mortality in Iran, resulting in the deaths of more than 29,000 individuals annually across the country.

Based on World Health Organization (WHO) data, only 1 in 5 individuals with hypertension have their blood pressure under control. Furthermore, clinical study results indicate that over 70% of hypertensive patients require more than one medication to achieve target blood pressure levels. Consequently, to ensure effective blood pressure control and enhance patient adherence, recent hypertension treatment guidelines strongly recommend initiating therapy with Fixed-Dose Combinations (FDCs)—two drugs formulated in a single pill—for the majority of patients.

The ARBICOR® Family: A Comprehensive and Effective Solution for Hypertension Management

The ARBICOR® family provides physicians and patients with a complete and versatile portfolio of blood pressure control medications. ARBICOR®, ARBICOR-PLUS®, and ARBITWIN® enable the selection of the most appropriate therapy for patients with varying levels of hypertension and underlying conditions, such as diabetes and metabolic disorders.

Cobel Darou, which previously pioneered the production of Telmisartan under the brand name ARBICOR® for the first time in Iran, followed by the combination drug Telmisartan/Hydrochlorothiazide branded as ARBICOR-PLUS®, has now made ARBITWIN® accessible to patients, further expanding its robust portfolio of therapeutic solutions for hypertension management.

ARBITWIN® is a Fixed-Dose Combination (FDC) of Telmisartan and Amlodipine in a single tablet, offering superior clinical efficacy and fewer side effects compared to the monotherapy of either medication.

Manufactured by Dr. Abidi Pharmaceuticals, alongside the other two medications in this family, ARBITWIN® is officially approved by the Iran Food and Drug Administration (IFDA) and is currently available by prescription in pharmacies nationwide.

About Cobel Darou

As a distinguished member of the Cobel Group, Cobel Darou has been operating for over 20 years in close collaboration with international pharmaceutical companies, specializing in the production, importation, and supply of under-license medications. By providing essential medications to patients, particularly specialty drugs, the company plays a pivotal role in elevating the community’s health standards and enhancing individuals’ quality of life.

IR-0327-ARB-3333-PR